Literature DB >> 23244246

The effect of adult and pediatric cardiopulmonary bypass on pharmacokinetic and pharmacodynamic parameters.

Annewil van Saet1, Saskia N de Wildt, Catherijne A J Knibbe, A D J J C Bogers, Robert J Stolker, Dick Tibboel.   

Abstract

Cardiopulmonary bypass (CPB) is known to have important effects on the disposition of drugs, which in turn may have important implications for the efficacy and toxicity of drug therapy. These effects constantly change throughout CPB and some continue to exert influence after the patient has been successfully weaned. In children, developmental and disease specific changes in drug disposition and effect also need to be taken into account when studying the effects of CPB. This review will provide an extensive overview of the current literature concerning the mechanisms behind the effects CPB has on pharmacokinetic and pharmacodynamic parameters. Also the effects of CPB on individual anesthetic drugs and sedatives, opioids, neuromuscular blocking agents, antibiotics and miscellaneous medications will be reviewed. Special attention will be paid to the pediatric population.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23244246     DOI: 10.2174/15748847113089990067

Source DB:  PubMed          Journal:  Curr Clin Pharmacol        ISSN: 1574-8847


  8 in total

1.  Pharmacokinetics of tranexamic acid in neonates and infants undergoing cardiac surgery.

Authors:  Ralph Gertler; Michael Gruber; Stanislas Grassin-Delyle; Saïk Urien; Klaus Martin; Peter Tassani-Prell; Siegmund Braun; Simon Burg; Gunther Wiesner
Journal:  Br J Clin Pharmacol       Date:  2017-03-31       Impact factor: 4.335

2.  Pharmacokinetics of cefuroxime in infants and neonates undergoing cardiac surgery.

Authors:  Ralph Gertler; Michael Gruber; Gunther Wiesner; Stanislas Grassin-Delyle; Saïk Urien; Peter Tassani-Prell; Klaus Martin
Journal:  Br J Clin Pharmacol       Date:  2018-06-15       Impact factor: 4.335

3.  Potentially clinically relevant concentrations of Cefazolin, Midazolam, Propofol, and Sufentanil in auto-transfused blood in congenital cardiac surgery.

Authors:  Gerda A Zeilmaker-Roest; Annewil van Saet; Joost van Rosmalen; Soma Bahmany; Antony van Dijk; Enno D Wildschut; Dick Tibboel; Ad J J C Bogers
Journal:  J Cardiothorac Surg       Date:  2018-06-08       Impact factor: 1.637

4.  Population Pharmacokinetic Modeling of Acetaminophen and Metabolites in Children After Cardiac Surgery With Cardiopulmonary Bypass.

Authors:  P Mian; A J Valkenburg; K Allegaert; B C P Koch; C V Breatnach; C A J Knibbe; D Tibboel; E H J Krekels
Journal:  J Clin Pharmacol       Date:  2019-01-11       Impact factor: 3.126

5.  Recovery of cefazolin and clindamycin in in vitro pediatric CPB systems.

Authors:  Gerdien A Zeilmaker-Roest; Annewil van Saet; Marloes P J van Hoeven; Birgit C P Koch; Joost van Rosmalen; Martina Kinzig; Fritz Söergel; Enno D Wildschut; Robert J Stolker; Dick Tibboel; Ad J J C Bogers
Journal:  Artif Organs       Date:  2020-01-06       Impact factor: 3.094

6.  Population Pharmacokinetic/Pharmacodynamic Modeling of Methylprednisolone in Neonates Undergoing Cardiopulmonary Bypass.

Authors:  Christoph P Hornik; Daniel Gonzalez; Julie Dumond; Huali Wu; Eric M Graham; Kevin D Hill; Michael Cohen-Wolkowiez
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2019-10-23

7.  An international survey of management of pain and sedation after paediatric cardiac surgery.

Authors:  Gerdien A Zeilmaker-Roest; Enno D Wildschut; Monique van Dijk; Brian J Anderson; Cormac Breatnach; Ad J J C Bogers; Dick Tibboel
Journal:  BMJ Paediatr Open       Date:  2017-07-05

8.  Intravenous morphine versus intravenous paracetamol after cardiac surgery in neonates and infants: a study protocol for a randomized controlled trial.

Authors:  Gerdien A Zeilmaker-Roest; Joost van Rosmalen; Monique van Dijk; Erik Koomen; Nicolaas J G Jansen; Martin C J Kneyber; Sofie Maebe; Greet van den Berghe; Dirk Vlasselaers; Ad J J C Bogers; Dick Tibboel; Enno D Wildschut
Journal:  Trials       Date:  2018-06-13       Impact factor: 2.279

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.